Evidence map›Paper›PMID 26483122›Full record

ArticleThe American journal of tropical medicine and hygiene2016

Quantitative Kinetoplast DNA Assessment During Treatment of Mucosal Leishmaniasis as a Potential Biomarker of Outcome: A Pilot Study.

Marlene Jara, Braulio Mark Valencia, Vanessa Adaui, Milena Alba, Rachel Lau, Jorge Arevalo, Alejandro Llanos-Cuentas, Andrea K Boggild

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Novel detection ofParasitology · 2024
    Article
  2. Article
  3. Review
  4. The American journal of tropical medicine and hygiene · 2020
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Marlene JaraInstituto de Medicina Tropical "Alexander von Humboldt," Universidad Peruana Cayetano Heredia, Lima, Peru; Public Health Ontario Laboratories, Public Health Ontario, Toronto, Canada; Department of Medicine, University of Toronto, Canada; Tropical Disease Unit, University Health Network Toronto General Hospital, Toronto, Canada.
Braulio Mark ValenciaInstituto de Medicina Tropical "Alexander von Humboldt," Universidad Peruana Cayetano Heredia, Lima, Peru; Public Health Ontario Laboratories, Public Health Ontario, Toronto, Canada; Department of Medicine, University of Toronto, Canada; Tropical Disease Unit, University Health Network Toronto General Hospital, Toronto, Canada.
Vanessa AdauiInstituto de Medicina Tropical "Alexander von Humboldt," Universidad Peruana Cayetano Heredia, Lima, Peru; Public Health Ontario Laboratories, Public Health Ontario, Toronto, Canada; Department of Medicine, University of Toronto, Canada; Tropical Disease Unit, University Health Network Toronto General Hospital, Toronto, Canada.
Milena AlbaInstituto de Medicina Tropical "Alexander von Humboldt," Universidad Peruana Cayetano Heredia, Lima, Peru; Public Health Ontario Laboratories, Public Health Ontario, Toronto, Canada; Department of Medicine, University of Toronto, Canada; Tropical Disease Unit, University Health Network Toronto General Hospital, Toronto, Canada.
Rachel LauInstituto de Medicina Tropical "Alexander von Humboldt," Universidad Peruana Cayetano Heredia, Lima, Peru; Public Health Ontario Laboratories, Public Health Ontario, Toronto, Canada; Department of Medicine, University of Toronto, Canada; Tropical Disease Unit, University Health Network Toronto General Hospital, Toronto, Canada.
Jorge ArevaloInstituto de Medicina Tropical "Alexander von Humboldt," Universidad Peruana Cayetano Heredia, Lima, Peru; Public Health Ontario Laboratories, Public Health Ontario, Toronto, Canada; Department of Medicine, University of Toronto, Canada; Tropical Disease Unit, University Health Network Toronto General Hospital, Toronto, Canada.
Alejandro Llanos-CuentasInstituto de Medicina Tropical "Alexander von Humboldt," Universidad Peruana Cayetano Heredia, Lima, Peru; Public Health Ontario Laboratories, Public Health Ontario, Toronto, Canada; Department of Medicine, University of Toronto, Canada; Tropical Disease Unit, University Health Network Toronto General Hospital, Toronto, Canada.
Andrea K BoggildInstituto de Medicina Tropical "Alexander von Humboldt," Universidad Peruana Cayetano Heredia, Lima, Peru; Public Health Ontario Laboratories, Public Health Ontario, Toronto, Canada; Department of Medicine, University of Toronto, Canada; Tropical Disease Unit, University Health Network Toronto General Hospital, Toronto, Canada andrea.boggild@utoronto.ca.
University Health Network · CAPublic Health Ontario · CA

Funding

Translational Research Development for Endemic Infectious Diseases of AmazoniaD43TW007120 · FIC · YALE UNIVERSITY · PI VINETZ, JOSEPH M. · 2004 to 2020
$3.0M
FIC NIH HHS D43 TW007120FIC NIH HHS D43TW007120
6 · The paper itself

Abstract

Mucosal leishmaniasis (ML) is a disfiguring manifestation of Leishmania (Viannia) infection. We evaluated parasite load (PL) over time as a potential biomarker of treatment outcome in ML. PL was assessed with kinetoplast DNA quantitative real-time polymerase chain reaction (kDNA-qPCR) at enrollment, days 14 and 21-28 of therapy and 3, 6, 12-18, and 18-24 months after treatment of ML and correlated to demographic, clinical, and parasitologic factors. Forty-four patients were enrolled: 30 men and 14 women. Enrollment PL differed significantly by causative species (P < 0.001), and was higher in patients with severe ML (nasal and laryngeal involvement) compared with those with only isolated nasal involvement (median = 1,285 versus 51.5 parasites/μg tissue DNA; P = 0.005). Two patterns of PL emerged: pattern 1 (N = 23) was characterized by a sequential decline in PL during and after therapy until kDNA was undetectable. Pattern 2 (N = 18) was characterized by clearance of detectable kDNA during treatment, followed by an increased PL thereafter. All patients who failed treatment (N = 4) demonstrated pattern 1. Leishmania (Viannia) braziliensis was overrepresented among those with pattern 2 (P = 0.019). PL can be quantified by cytology brush qPCR during and after treatment in ML. We demonstrate that treatment failure was associated with undetectable PL, and L. (V.) braziliensis infection was overrepresented in those with rebounding PL.

Indexed as

AdolescentAdultAgedAged, 80 and overAmphotericin BAntimony Sodium GluconateBiomarkersChildDNA, KinetoplastDNA, ProtozoanFemaleHumansLeishmaniasis, MucocutaneousMaleMiddle AgedPilot ProjectsAmphotericin BAntimony Sodium GluconateBiomarkersDNA, KinetoplastDNA, Protozoan

Identifiers

PMID26483122
PMCPMC4710413
OpenAlexW2179298477

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.